In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
|Articles|August 22, 2012
The Challenges in Manufacturing Biologics [Video]
This content is brought to you by Amgen This video summarizes the complex process of creating biologics from start to finish and describes some of the unique challenges-- and tremendous effort-- involved in delivering safe and effective biologics.
Advertisement
This content is brought to you by Amgen
This video summarizes the complex process of creating biologics from start to finish and describes some of the unique challenges-- and tremendous effort-- involved in delivering safe and effective biologics.
Advertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
2
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
3
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5